Barrett’s Esophagus
Studies have shown that copy number increases in ERBB2 (17q12), MYC (8q24), or ZNF217 (20q13) are associated with high grade dysplasia/ adenocarcinoma while copy number decrease of the 9p21 locus is associated with low or high grade dysplasia.1 Additional studies have shown that patients with a histologic response to photodynamic therapy (the absence of high grade dysplasia) who have copy number increases in either ERBB2, MYC, ZNF217 or copy number decrease in 9p21 appear to be a higher risk of developing recurrent high grade dysplasia.2
FISH Assays:
ERBB2 (17q12): Copy number increase is associated with high grade dysplasia/ adenocarcinoma and increased risk of recurrence.
MYC (8q24 ): Copy number increase is associated with high grade dysplasia/ adenocarcinoma and increased risk of recurrence.
ZNF217 (20q13): Copy number increase is associated with high grade dysplasia/ adenocarcinoma and increased risk of recurrence.
P16 (9p21): Copy number decrease is associated with high grade dysplasia/ adenocarcinoma and increased risk of recurrence.
References
- Brankley SM, Wang KK, Harwood AR, Miller DV, Legator MS, Lutzke LS, Kipp BR, Morrison LE, Halling KC.: The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett’s esophagus. J Mol Diagn. 2006 May;8(2):260-7.
- Prasad GA, Wang KK, Halling KC, Buttar NS, Wongkeesong LM, Zinsmeister AR, Brankley SM, Westra WM, Lutzke LS, Borkenhagen LS, Dunagan K.: Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer. 2008 Aug 1;113(3):470-6.